Director Andrew Lauck filed a Form 4 with the SEC on November 9, 2026, disclosing an open-market purchase of Class A common stock in Strata Critical Medical, Inc. (NASDAQ:SRTA) on November 5, 2026.
Key Highlights
- Reporting person: Andrew Lauck, identified as a Director of Strata Critical Medical, Inc.
- Transaction: Purchase (transaction code P) of 2,000 shares of Class A common stock, $0.0001 par value per share, on November 5, 2026.
- Price paid: $4.999 per share, according to the filing.
- Post-transaction ownership: Lauck directly beneficially owned 172,902 shares following the reported transaction.
- Filing signed: Melissa M. Tomkiel, as attorney-in-fact for Andrew C. Lauck, signed the form on November 9, 2026.
Director Lauck's November 5 Purchase of Strata Critical Medical Stock
According to the Form 4 filing, Andrew Lauck, a Director at Strata Critical Medical, Inc., acquired 2,000 shares of the company's Class A common stock, $0.0001 par value per share, in an open-market purchase on November 5, 2026. The filing records the per-share price as $4.999. The transaction is coded "P," indicating a purchase rather than a disposition.
Following this transaction, the filing reports that Lauck directly beneficially owned 172,902 shares of Class A common stock. No derivative securities transactions were reported in Table II of the filing. The filing does not indicate that the transaction was made pursuant to a Rule 10b5-1(c) plan, as the corresponding checkbox on the form was not checked.
The form was filed by one reporting person and was signed by Melissa M. Tomkiel as attorney-in-fact for Andrew C. Lauck on November 9, 2026. The issuer is identified in the filing as Strata Critical Medical, Inc., with the ticker symbol SRTA listed on NASDAQ. The company's address listed for the reporting person is 666 Third Avenue, 25th Floor, New York, New York 10017.
What Was Disclosed
The filing disclosed a purchase of 2,000 shares of Strata Critical Medical, Inc. Class A common stock by Director Andrew Lauck at $4.999 per share on November 5, 2026, bringing his direct beneficial ownership to 172,902 shares.




Please wait processing your request...